Lumendi

Executive Summary

Lumendi, founded in 2017 and headquartered in London, UK, is a medical device company focused on transforming gastrointestinal (GI) interventions through its proprietary DiLumen® Endoluminal Interventional Platform (EIP). Designed in collaboration with GI and colorectal practitioners, DiLumen enables faster, safer, and less invasive complex polypectomies and other endoscopic procedures. The platform addresses a critical unmet need in therapeutic endoscopy, where traditional tools limit access and visualization for challenging lesions. By providing a stable, multi-channel platform with enhanced visualization, DiLumen aims to reduce procedure time, improve outcomes, and expand the range of treatable conditions endoscopically, potentially reducing the need for surgical intervention. Lumendi has gained traction in select markets, with early clinical adoption demonstrating safety and efficacy. The company is well-positioned to capture share in the growing endoluminal surgery market, driven by an aging population and increased colorectal cancer screening. However, as a private firm, financial details remain undisclosed. Key near-term catalysts include regulatory clearances (e.g., FDA 510(k) for expanded indications), publication of pivotal clinical data supporting further adoption, and potential strategic partnerships or distribution agreements to accelerate commercialization. Investors should monitor these developments closely, as successful execution could drive significant value creation.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for Expanded Indications70% success
• Q2 2026Publication of Pivotal Clinical Study Results60% success
• Q4 2026Strategic Partnership or Distribution Agreement in US/EU50% success